Upload
stephan-o-krause-phd
View
67
Download
3
Tags:
Embed Size (px)
Citation preview
Stephan KrauseDirector, QA TechnologyAstraZeneca Biologics
CASSS CMC Strategy Forum09 December 2014 Tokyo, Japan
Risk-Based Analytical Life Cycle Steps for Accelerated Products
2
Outline
• Review of Specifications and CMC Processes: Opportunities and Considerations
• Review of Strategic Opportunities to Reduce Analytical Method Lifecycle Steps
for Accelerated Programs for:
- Analytical Platform Technology (APT) methods- Product and Process Characterization methods- Product-Specific (“New”) methods - Compendial methods
• Goal: Understand how analytical platform technology and parallel (versus
sequential) analytical method and specification lifecycle steps can greatly
support accelerated development programs.
• Presentation to Focus on Late-Stage Development Opportunities:
- Mostly Risk(s) to Manufacturer/Sponsor 2
3
CQA Development, CMC Changes, and Specifications
From: Krause, S., WCBP, 30Jan13, Washington, DC.
FTIH POC BLA
Tox StudiesPhase 1
Phase 2Phase 3
Clinical ResupplyMfg/Formulation Change(s)
Specifications Revision(s)
Negotiations, Final Commercial Specifications
QTPP
Final CQAs & Control Strategy Approval
Potential CQAsProduct & Process Design
Life-CycleManagement
POST-APPROVALCHANGES
PHASE 3PHASE 1/2Pre-IND
CQ
A D
eve
lop
me
nt
(Qb
D P
roc
ess
)S
pe
cs
Lif
e C
yc
le
Mg
mt
CM
C a
nd
Te
ch
T
ran
sfe
r P
roc
ess Analytical
Manufacturing
Strategic or Tactical Changes
Method qualification
Dose change
Delivery Device
PQ lots
Setting of Initial Specifications
Specifications Revision(s)
Mfg Transfer
Method validation
Method transfer
Formulation Change
Process Verification
Method Maintenance
Global Supply
Commercial Specifications
Accelerated CQA Development, CMC Changes, and Specifications
4
FTIH POC BLA
Tox StudiesPhase 1
Phase 3
Clinical ResupplyMfg/Formulation Change(s)
Specifications Revision(s)
Commercial Specifications Negotiations, Final
Commercial Specifications and/or Post-BLA
commitmens
QTPP
Final CQAs & Control Strategy Approval
Potential CQAsProduct & Process Design
Life-CycleManagement
POST-APPROVALCHANGES
PIVOTAL PHASE (3)PHASE 1 Pre-IND
CQ
A D
evel
op
men
t(Q
bD
Pro
cess
)S
pec
s L
ife
Cyc
le
Mg
mt
CM
C a
nd
Tec
h
Tra
nsf
er P
roce
ss Analytical
Manufacturing
Strategic or Tactical Changes
Method qualification
Dose change
Delivery Device
PQ lots
Setting of Initial Specifications
Mfg Transfer
Method validation
Method transfer
Formulation Change
Process Verification
Method Maintenance
Global Supply
Method Change
Accelerated Development
From: Krause, S., CaSSS CMC Strategy Forum, 27Jan14, Washington, DC.
Accelerated CQA Development, CMC Changes, and Specifications
5
From: Krause, S., CaSSS CMC Strategy Forum, 27Jan14, Washington, DC.
FTIH POC BLA
Tox StudiesPhase 1
Phase 3
Clinical ResupplyMfg/Formulation Change(s)
Specifications Revision(s)
Commercial Specifications
QTPP
Final CQAs & Control Strategy Approval
Potential CQAsProduct & Process Design
Life-CycleManagement
POST-APPROVALCHANGES
PIVOTAL PHASE (3)PHASE 1 Pre-IND
CQ
A D
evel
op
men
t(Q
bD
Pro
cess
)S
pec
s L
ife
Cyc
le
Mg
mt
CM
C a
nd
Tec
h
Tra
nsf
er P
roce
ss Analytical
Manufacturing
Strategic or Tactical Changes
Method qualification
Dose change
Delivery Device
PQ lots
Setting of Initial Specifications
Mfg Transfer
Method validation
Method transfer
Formulation Change
Process Verification
Method Maintenance
Global Supply
Method Change
Accelerated Development
CompLots
Accelerated CQA Development, CMC Changes, and Specifications
6
From: Krause, S., CaSSS CMC Strategy Forum, 27Jan14, Washington, DC.
FTIH POC BLA
Tox StudiesPhase 1
Phase 3
Clinical ResupplyMfg/Formulation Change(s)
Specifications Revision(s)
Commercial Specifications
QTPP
Final CQAs & Control Strategy Approval
Potential CQAsProduct & Process Design
Life-CycleManagement
POST-APPROVALCHANGES
PIVOTAL PHASE (3)PHASE 1 Pre-IND
CQ
A D
evel
op
men
t(Q
bD
Pro
cess
)S
pec
s L
ife
Cyc
le
Mg
mt
CM
C a
nd
Tec
h
Tra
nsf
er P
roce
ss Analytical
Manufacturing
Strategic or Tactical Changes
Method qualification
Dose change
Delivery Device
PQ lots
Setting of Initial Specifications
Mfg Transfer
Method validation
Method transfer
Formulation Change
Process Verification
Method Maintenance
Global Supply
Method Change
Accelerated Development
CompLots
PQ lotsCompLots =
PQ Lots = Comparability Lots
7
FTIH POC BLA
Tox StudiesPhase 1
Phase 3
Clinical ResupplyMfg/Formulation Change(s)
Specifications Revision(s)
Commercial Specifications
QTPP
Final CQAs & Control Strategy Approval
Potential CQAsProduct & Process Design
Life-CycleManagement
POST-APPROVALCHANGES
PIVOTAL PHASE (3)PHASE 1 Pre-IND
CQ
A D
evel
op
men
t(Q
bD
Pro
cess
)S
pec
s L
ife
Cyc
le
Mg
mt
CM
C a
nd
Tec
h
Tra
nsf
er P
roce
ss Analytical
Manufacturing
Strategic or Tactical Changes
Method qualification
Dose change
Delivery Device
PQ lots
Setting of Initial Specifications
Mfg Transfer
Method validation
Method transfer
Formulation Change
Process Verification
Method Maintenance
Global Supply
Method Change
Accelerated Development
CompLots
PQ lotsCompLots =
How to manage two sets of acceptance criteria (commercial specifications vs. equivalence/non-inferiority limits) for same sets of results ?
Typical Analytical Method and Specification Lifecycle(s)
8
AMVStudies
Start PV Stage 2(PQ Lots)
Maintenance (continuous
AMV)
AMT Studies
Commercial Specifications
Method Qualified
Pivotal/Phase 3 Specifications
Phase 1/2 Specifications
Sp
ecs covered
in A
MV
?
From: Krause, S., PDA Journal of Pharmaceutical Science and Technology, Jan/Feb 2015.
9
Specification Setting Process
Acceptance Criteria
Existing Knowledge of Mfg/Analytical
Capability
Historical Data from this
specific Product and Process
Clinical Consideration
and/or Experience
“Platform” Knowledge from Similar Product
and Process
From: Krause, S., WCBP, 30Jan13, Washington, DC.
Specification Example (% Purity): Manufacturing Capability vs. Clinical Experience
10
From: Krause, S., PDA Journal of Pharmaceutical Science and Technology, Jan/Feb 2015.
95.0
96.0
97.0
98.0
99.0
100.0
NLT 95.0%
Tig
hte
n D
P S
hel
f-L
ife
Lim
it
N=12 DP batches (clinical phase 2
and 3)
Historical DP Release Results (T=0M)
DP Stability Results – Recommended Temperature
Estimated Clinical Purity Patient Exposure Level
(for 3-year old DP)
NLT 97.0%
NLT 97.6%
Proposed Shelf-Life Specification (3 Years) Based on Predicted
Manufacturing Capability (3 SD; n=12)
Specification Example (% Purity): Manufacturing Capability vs. Clinical Experience
11
From: Krause, S., PDA Journal of Pharmaceutical Science and Technology, Jan/Feb 2015.
95.0
96.0
97.0
98.0
99.0
100.0
NLT 95.0%
Tig
hte
n D
P S
he
l f-L
ife
Lim
it
N=12 DP batches (clinical phase 2
and 3)
Historical DP Release Results (T=0M)
DP Stability Results – Recommended Temperature
Estimated Clinical Purity Patient Exposure Level
(for 3-year old DP)
NLT 97.0%
NLT 97.6%
Proposed Shelf-Life Specification (3 Years) Based on Predicted
Manufacturing Capability (3 SD; n=12)
Specification Example (% Purity): Manufacturing Capability vs. Clinical Experience
12
From: Krause, S., PDA Journal of Pharmaceutical Science and Technology, Jan/Feb 2015.
95.0
96.0
97.0
98.0
99.0
100.0
NLT 95.0%
Tig
hte
n D
P S
hel
f-L
ife
Lim
i t
N=12 DP batches (clinical phase 2
and 3)
Historical DP Release Results (T=0M)
DP Stability Results – Recommended Temperature
Estimated Clinical Purity Patient Exposure Level
(for 3-year old DP)
NLT 97.0%
NLT 97.6%
Proposed Shelf-Life Specification (3 Years) Based on Predicted
Manufacturing Capability (3 SD; n=12)
Difference Acceptable ?
13
Analytical Method Lifecycle – Intended Use
Analytical Method Selection
Pharmaceutical Development Supporting Studies:Process characterizationProduct characterizationProcess validation
Routine Testing (registered methods):Raw materialsIn-process Release Stability
Intended Use (defined)
AMD Studies
AMD Studies
AMQ ReportAMQ Report
Intended Use (re-defined)
AMV Report
IdentitySafetyPurity
QualityPotency
Quality Target Product Profile (QTPP)Critical Quality Attributes (CQA)
Critical Process Parameters (CPP)
From: Krause, S., PDA Technical Report 57, 2012.
14
Retrospective and Prospective Use of Data for AMV Studies from other Processes Prior to AMV – New Method
Krause/PDA Workshop (2013)
15
Retrospective and Prospective Use of Data for AMV Studies from other Processes Prior to AMV – Analytical Platform Method
Method Qualification
(AMQ)
Method Validation (AMV)
Method Transfer (AMT)
(Less)AMQ
Studies
“Verification” Focus on: Accuracy, Specificity
PVFTIH BLA
Historical Data - SU
Assay Control
Tech Transfer
(Less) Interm.
Precision & Reprod.
Historical Data - RU
Assay Control
“Approved” Method
Krause/PDA Workshop (2013)
Ideal Analytical Method Lifecycle Clinical Phase 1-2 (prior to transfer from Pilot to Commercial Plant)
16
DS/DPSpecificationTest Methods
for New Method
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
Start PV Stage 2(PQ Lots)
Completed
In progress
Not started
AMV completed
Maintenance(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
Process Color Legend:
Method Qualified
(SOP Lock)
Ideal Analytical Method Lifecycle Preparing for Tech Transfer (Pilot to Commercial Plant)
17
DS/DPSpecificationTest Methods
for New Method
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
Start PV Stage 2(PQ Lots)
Completed
In progress
Not started
AMV completed
Maintenance(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
Process Color Legend:
Method Qualified
(SOP Lock)
Ideal Analytical Method Lifecycle Preparing for Tech Transfer (Pilot to Commercial Plant)
18
DS/DPSpecificationTest Methods
for New Method
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
Start PV Stage 2(PQ Lots)
Completed
In progress
Not started
AMV completed
Maintenance(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
Process Color Legend:
Method Qualified
(SOP Lock)
Ideal Analytical Method Lifecycle Preparing for Tech Transfer (Pilot to Commercial Plant)
19
DS/DPSpecificationTest Methods
for New Method
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
Start PV Stage 2(PQ Lots)
Completed
In progress
Not started
AMV completed
Maintenance(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
Process Color Legend:
Method Qualified
(SOP Lock)
Ideal Analytical Method Lifecycle Preparing for PQ (at Commercial Plant)
20
DS/DPSpecificationTest Methods
for New Method
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
Start PV Stage 2(PQ Lots)
Completed
In progress
Not started
AMV completed
Maintenance(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
Process Color Legend:
Method Qualified
(SOP Lock)
Ideal Analytical Method Lifecycle Preparing for PQ (at Commercial Plant)
21
DS/DPSpecificationTest Methods
for New Method
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
Start PV Stage 2(PQ Lots)
Completed
In progress
Not started
AMV completed
Maintenance(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
Process Color Legend:
Method Qualified
(SOP Lock)
Ideal Analytical Method Lifecycle Executing PQ Studies (at Commercial Plant)
22
DS/DPSpecificationTest Methods
for New Method
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
PQ Lots Mfg
Completed
In progress
Not started
AMV completed
Maintenance(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
Process Color Legend:
Method Qualified
(SOP Lock)
Analytical Method Lifecycle APT Opportunities following AMV Study Completion
23
DS/DPSpecification
Test Methods for Same SOP andNew Product
Robustness Studies Execution
QCDev.
AMVStudies
(QC-Comm.)
PQ Lots Mfg
Completed
In progress
Not started
AMV completed
MaintenanceAMM
(QC-Comm.)
Robustness Studies
Master Plan
AMT Studies
(QC-Dev. & QC-Comm.)
SOP-specific Min/Max Method
Conditions (for PB Design)
Commercial Specifications
Not Parallel Step
APT MethodAMV and AMM
(QC)
Analytical Platform Technology
APT Method
Robustness and AMT
Process Color Legend:
Method Qualified
(SOP Lock)
APT Method
AMQ
Analytical Method Lifecycle for Accelerated ProgramsAPT Opportunities following prior AMV Study Completion
24
DS/DP Specification
APT Test Methods (not compendial)
APT Transfer (feasibility only, no formal AMT)
Partial AMV StudyExecution
Start PV Stage 2
(PQ Lots)
APT Maintenance
VMP Analytical Methods
APT Qualification
Studies
Commercial Specifications
APT Robustness
(QC-Dev.)
Feasibility Testing
(QC-Comm.)
Simultaneous ?
Simultaneous ?
Completed
In progress
Not started
AMV completed
Not Parallel Step
Analytical Platform Technology
Process Color Legend:
Analytical Method Lifecycle for Accelerated ProgramsAdditional APT Opportunities
25
Qualification of Test Methods
Process and/or Product
Characterization
Representative Samples
Available (Dev.)
Execution Reqs: (1. IOQ Instrument)(2. Analyst Training)3. Final SOP version
QC Dev. or QC Comm.
Confirm Method
Suitability
Start PV Stage 2(PQ Lots)
Qualify (as relevant):A. Accuracy/MatchingB. Precision/Reliability
C. SpecificityD. DL or QL
Qualification Report(s)
Method Qualification Master Plan
Final PV Process Ranges and/or Analytical Control Strategy
APT (Reduced) Qualification Opportunity
Completed
In progress
Not started
AMV completed
Not Parallel Step
Analytical Platform Technology
Process Color Legend:
Analytical Method Lifecycle for Accelerated ProgramsLimited APT Opportunities
26
DS/DPSpecificationTest MethodsCompendial
Representative DS/DP Samples (from QC-Dev. or QC-Comm.)
Execution Reqs: 1. IOQ Instrument2. Analyst Training
3. Qualified Material4. Final SOP version
Start PV Stage 2(PQ Lots)
Completed
In progress
Not started
AMV completed
Verify (as relevant):A. Accuracy/MatchingB. Precision/Reliability
C. SpecificityD. DL or QL
Verification Report(s)
Method Verification Master Plan
Commercial Specifications
Not Parallel Step
Process Visual Legend:
QC Comm.
Risk/Uncertainty Levels and Risk-Based Opportunities (Typical)(Analytical Method Lifecycle Steps in Typical Order)
27
AMQ-Robustness-AMT-AMV Class Description Typical
Risk / Uncertainty
Level (1=Low, 5=High)
Suggested Prospective AMQ Studies
(QC-Dev.)
Suggested Prospective Robustness
Studies(QC-Dev.)
Suggested Prospective AMT Studies(QC-Dev./ QC-
Comm.)
Suggested Prospective AMV Studies(QC Comm.)No.
Analytical Method
Product / Process Sample
A New New 4-5Full
Qualification
Full Robustness
Studies
Full AMT studies
Full Validation
B NewOld
(Validated)3-4(1)
Full Qualification Plus AMC(2)
Studies
Full Robustness
Studies
Full AMT Studies
Full Validation Plus AMC(2)
Studies
CAnalytical Platform
TechnologyNew 1-2 Qualification
Robustness Studies
AMT Studies Validation
D Compendial New 1-2Verification
per USP <1226>
N/A N/AVerification
per USP <1226>
EProduct/Process Charaterization
TestsNew 2-3 Qualification N/A N/A N/A
(1) If a new analytical method (forced method replacement) is needed due to supply reasons, the risk level can be generally considered higherbecause no other option may exist. Unforced test method replacements can be considered to be a lower risk level as more time may be availableto optimize the method performance.(2) AMC = Analytical Method Comparability: A study to confirm that a new analytical method can perform equally or better than the existing one.
Krause/PDA-DHI Publications, 2007, PDA TR 57 (2012)
28
Summary
• Opportunities exist to reduce typical analytical method
lifecycle steps for accelerated programs.
• Use of (analytical) platform technology can greatly support
accelerated development programs.
• Reduction and/or use of “parallel” analytical method lifecycle
steps during later-stage development (prior to PV stage 2)
results in risk(s) mostly to manufacturer/sponsor and not the
patient.
28